Last reviewed · How we verify
NCT06308588
Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Recruiting now
Phase 1, PHASE2
Last updated 14 April 2026
What this trial tests
Phase 1, PHASE2 trial testing Blinatumomab in Philadelphia Chromosome-Positive in 40 participants. Currently enrolling.
Timeline
5 August 2024
Primary endpoint
1 May 2027
1 May 2027
1 May 2029
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 5 August 2024 |
| Primary completion | 1 May 2027 |
| Estimated completion | 1 May 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Blinatumomab (blinatumomab) — full drug profile →
- Asciminib (ASCIMINIB) — full drug profile →
Conditions studied
- Philadelphia Chromosome-Positive — all drugs for Philadelphia Chromosome-Positive →
- Acute Lymphoblastic Leukemia — all drugs for Acute Lymphoblastic Leukemia →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Philadelphia Chromosome-Positive or Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To learn if the combination of blinatumomab and asciminib can help to control Ph+ ALL.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Asciminib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Case Series and Review of Emerging Evidence.
Mohammed Saleh MF, Nasiri A, Abdrabou AK, Samarkandi H, et al · · 2026 · PMID 42042193 · DOI 10.3390/hematolrep18020028 -
Efficacy and safety of blinatumomab combination therapy in high-risk B-cell acute lymphoblastic leukemia: A systematic review and meta-analysis.
Wang M, Yu X, Zou Z, He Y, et al · · 2026 · PMID 41947896 · DOI 10.3892/ol.2026.15552 -
Asciminib and inotuzumab ozogamicin: a new combination for highly refractory Ph-positive B-cell acute lymphoblastic leukemia.
Strumilowska A, Devitt K, Conant J, Gardner JA, et al · · 2025 · PMID 41036242 · DOI 10.1016/j.lrr.2025.100546 -
Upfront Immunotherapy Approaches in the Management of Adults with Acute Lymphoblastic Leukemia.
Shahzad M, Amin MK, Badar T. · · 2025 · PMID 40940843 · DOI 10.3390/cancers17172746 -
Plenary Abstracts Session & Oral Presentations
· 2025 -
Overcoming B-ALL Resistance to Targeted and Immune Therapies by Rational Combination Strategies.
Quijada-Álamo M, Freed G, Wagenblast E. · · 2025 · PMID 40287957 · DOI 10.1158/2643-3230.bcd-25-0036
Verify or expand the search:
- PubMed search for NCT06308588
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blinatumomab
Trials testing the same drug.
- NCT07192237 — Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Diseas · Phase 2 · not yet recruiting
- NCT07178912 — Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromoso · Phase 2 · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
- NCT06991920 — Immune-targeted Combination With Chemotherapy for Acute Leukemia of Ambiguous Lineage · NA · not yet recruiting
- NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT06308588 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 14 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06308588.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing